NCT01039922 SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
| NCT ID | NCT01039922 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Condition | Neuroendocrine Tumors |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,245 participants |
| Start Date | 2008-01 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,245 participants in total. It began in 2008-01 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. So far, there is still uncertainty about the cell biology and mechanistic regulation of these tumours. Therefore targeted treatment is limited and management challenging. Treatment options include surgery, medical and ablative therapy, and more recently peptide-receptor radionuclide therapy. In order to better understand the characteristics of GEP-NETs and to evaluate treatment strategies, the SwissNET registry aims at the collection of data from patients presenting with a GEP-NET in Switzerland. Data will be entered prospectively and anonymized in a specifically designed database after the patient has given informed consent. All hospitals and general practitioners are invited to report on patients with a GEP-NET diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focussing on types of GEP-NETs, treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate), thereby contributing to the better understanding of these tumours.
Eligibility Criteria
Inclusion Criteria: * Neuroendocrine tumor irrespective of primary tumor location * Diagnosis in Switzerland * Given informed consent
Contact & Investigator
Aurel Perren, MD
STUDY DIRECTOR
Institute of Pathology, University of Bern, Bern
Frequently Asked Questions
Who can join the NCT01039922 clinical trial?
This trial is open to participants of all sexes, studying Neuroendocrine Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01039922 currently recruiting?
Yes, NCT01039922 is actively recruiting participants. Contact the research team at Alexander.Siebenhuener@usz.ch for enrollment information.
Where is the NCT01039922 trial being conducted?
This trial is being conducted at Aarau, Switzerland, Aarberg, Switzerland, Affoltern am Albis, Switzerland, Altdorf, Switzerland and 11 additional locations.
Who is sponsoring the NCT01039922 clinical trial?
NCT01039922 is sponsored by Insel Gruppe AG, University Hospital Bern. The principal investigator is Aurel Perren, MD at Institute of Pathology, University of Bern, Bern. The trial plans to enroll 1,245 participants.